TDZD-8 NEW
| Price | $42 | $53 | $77 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-27 |
Product Details
| Product Name: TDZD-8 | CAS No.: 327036-89-5 |
| Purity: 99.60% | Supply Ability: 10g |
| Release date: 2026/07/27 |
Product Introduction
Bioactivity
| Name | TDZD-8 |
| Description | TDZD-8 (NP 01139) is an inhibitor of GSK-3β, with an IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC. |
| In vitro | TDZD-8 acts as a noncompetitive inhibitor of ATP or GS-1 binding. TDZD-8 shows no inhibition of PKA, PKC, Cdk-1/cyclin B or CK-II in kinase assays. [1] TDZD-8 specifically induces cell death of primary leukemia specimens. TDZD-8 ablates leukemia progenitor and stem cells. TDZD-8 treatment induces oxidative stress. TDZD-8 induces cell death with extremely rapid cell death kinetics showing loss of membrane integrity. TDZD-8 inhibits PKC and FLT3 in primary AML specimens. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 125 mg/mL (562.4 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (44.99 mM), Solution. Ethanol : 44.5 mg/mL (200.22 mM), Sonication is recommended. 10% DMSO+90% Saline : < 10 mg/mL (44.99 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. |
| Keywords | TDZD-8 | TDZD8 | TDZD 8 | NP-01139 | NP01139 | Inhibitor | inhibit | GSK-3β | GSK-3beta Inhibitor I | GSK-3b Inhibitor I | GSK-3 | GSK3 | Glycogen synthase kinase-3 | Glycogen synthase kinase 3 |
| Inhibitors Related | Cromolyn sodium | 4-Methyl-6-Methoxycoumarin | Indazole | GSK 3 Inhibitor IX | AT7519 | 5-Bromoindole | 4-Chloro-2'-bromoacetophenone | Ethyl linoleate | Ceftriaxone sodium hydrate | Ginsenoside Rg2 | GSK-3 Inhibitor 5 | ROCK-IN-5 |
| Related Compound Libraries | PI3K-AKT-mTOR Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Anti-Ovarian Cancer Compound Library | Inhibitor Library | Neuroprotective Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1970.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-07-27 | |
|
VIP2Y
|
Shenzhen Nexcon Pharmatechs Ltd.
|
2026-08-03 | ||
| $200.00 |
VIP3Y
|
Henan Fengda Chemical Co., Ltd
|
2026-07-09 | |
| $2.00 |
VIP9Y
|
Career Henan Chemical Co
|
2019-07-06 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY